唾液腺感染症の世界市場：タイプ別、用途別、国別、企業の分析（2024年～2032年）

唾液腺感染症の市場規模

世界の唾液腺感染症の市場規模は、2023年に29億3,000万米ドル、2032年までに47億2,000万米ドルに達すると予測され、2024年～2032年にCAGRで5.44%の成長が見込まれます。市場は主に、疾患のパターンの変化、環境の変化、さまざまな唾液腺感染症の流行などによって伸びると予測されます。研究開発と臨床試験に向けた資金調達の増加による製品開発の向上も、市場拡大の重要な促進要因です。市場は主に、診断と治療の選択肢の進歩、セルフケア意識の向上、衛生習慣の改善によって牽引されます。

世界の唾液腺感染症の概要

唾液腺感染症は、唾液腺または唾液管が細菌やウイルスに感染することで起こります。唾液の流量の低下は、唾液管の閉塞や炎症によってもたらされる可能性があり、これが感染の原因となることもあります。この疾患は唾液腺炎として知られています。唾液腺感染症は乳幼児を含め誰にでも発症する可能性がありますが、高齢者や長期的に病気を患っている人が特にかかりやすい疾患です。唾液腺炎として知られる疾患は、1つ以上の唾液腺の腫脹と炎症によって特徴づけられます。急性型と慢性型の両方が存在します。唾液腺炎の正確な原因は不明です。唾石症、すなわち唾液腺結石の生成は、時にこの疾患と関連することがあります。

唾液腺炎の結果として、1つまたは複数の唾液腺が腫れたり、敏感になったり、赤くなったりすることがあります。唾液腺には、耳の近くにある耳下腺、舌下腺、顎下腺に加えて、舌、唇、頬、口蓋にある複数の小さな腺が含まれます。これらの腺の分泌物は、唾石、または結石によって妨げられることがあります。

時には、唾液腺が感染し、発熱などを生じることもあります。唾液腺炎の急性型と慢性型の両方に共通する特徴は、唾液の流量の減少です。食事中は痛みが顕著になり、患者の75％以上が口渇（口腔乾燥症）を訴えます。その他の病状としては、サルコイドーシス、脱水、栄養不良、がんの放射線治療、ヘルペス、HIV、A型/II型インフルエンザ、I型/II型パラインフルエンザ、唾液結石、唾液管を塞ぐ粘液、腫瘍、シェーグレン症候群、サルコイドーシス、不十分な口腔衛生などがあり、これらは唾液分泌を減少させ唾液腺炎を引き起こす可能性があります。

唾液腺感染症市場の成長促進要因

感染率の上昇

唾液腺感染症の代替治療法に対するニーズは、感染症、特に細菌、真菌、ウイルス感染症の流行によってもたらされることがほとんどです。真菌感染症、細菌性唾液腺炎、流行性耳下腺炎のような疾患の有病率は、歯の不衛生、ライフスタイルの変化、抗生物質に耐性を持つ細菌の登場の結果として頻繁に上昇しています。このような例の増加は、効率的な治療および診断のアプローチの必要性を明示しています。

唾液腺の健康の重要性についての知識が深まるにつれて、医療従事者はこれらの感染症の特定と治療により注意を払うようになってきています。このような関心の高まりの結果、患者は早期に治療を受けるようになり、最先端の治療の選択肢に対する需要が増加しています。さらに、患者の転帰を改善することを目的とした研究活動の活発化と治療技術の進歩により、市場の発展可能性は強化されます。

唾液腺感染症市場の概要：地域別

さまざまな発展の促進要因や障害がある中で、世界の唾液腺感染症市場は、すべての地域にわたって全体的に伸びています。治療選択がより広く知られ、アクセスしやすくなるかぎり、業界は発展すると予測されます。

唾液腺感染症企業のニュース

2022年8月、オーストラリアで、がんや心臓病のリスクを調べる世界初のDNAスクリーニングプログラムが導入されました。この取り組みはオーストラリアのモナシュ大学が率いる全国的な共同研究です。

2022年6月、Goodbody Health Inc.は、遺伝子解析を用いて個人の心臓病やがんの10年にわたる発症リスクを推定する4つの新しい検査を導入しました。これらの開始により、このセグメントの将来の成長が加速すると予測されます。

当レポートでは、世界の唾液腺感染症市場について調査し、市場規模と成長率、成長促進要因と課題、各地域の市場シェア、主要企業の分析などを提供しています。

目次

第1章 イントロダクション

第2章 調査と調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題

第5章 世界の唾液腺感染症市場

第6章 世界の唾液腺感染症の市場シェアの分析

• タイプ別
• 用途別
• 国別

第7章 タイプ - 世界の唾液腺感染症市場

• 診断
• 治療

第8章 用途 - 世界の唾液腺感染症市場

• 病院
• 診療所
• 家庭
• その他

第9章 国 - 世界の唾液腺感染症市場

• 北米
  • 米国
  • カナダ
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ベルギー
  • オランダ
  • トルコ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • タイ
  • マレーシア
  • インドネシア
  • ニュージーランド
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 ポーターのファイブフォース分析

第11章 SWOT分析

第12章 主要企業の分析

• AbbVie Inc.
• Allergan plc.
• AstraZeneca
• FUJIFILM Holdings Corporation
• General Electric Company
• GlaxoSmithKline plc.
• Merck & Co
• Pfizer Inc.
• Siemens Healthcare GmbH

Salivary Gland Infection Market Size

The Salivary Gland Infection market is expected to reach US$ 2.93 Billion in 2023 to US$ 4.72 Billion by 2032, with a CAGR of 5.44 % from 2024 to 2032. The market is expected to rise due in large part to changing disease patterns, environmental changes, and the rising prevalence of various salivary gland infections. Improved product development as a result of increased financing for R&D and clinical trials is another important driver of market expansion. The market is mostly driven by advances in diagnosis and treatment choices, more self-care awareness, and improved hygiene practices.

Global Salivary Gland Infection Overview

A salivary gland infection happens when the salivary gland or duct is infected by bacteria or viruses. Reduced saliva flow, which may be brought on by an obstruction or inflammation of the salivary duct, may be the cause of the infection. The illness is known as sialadenitis. While salivary gland infections can strike anybody, including infants, the elderly and those with long-term illnesses are particularly vulnerable to the ailment. The illness known as salivalentitis is typified by swelling and inflammation of one or more salivary glands. Both acute and chronic versions exist. Unknown is the precise cause of sialadenitis. Sialolithiasis, or the production of salivary gland stones, may occasionally be linked to the disorder.

One or more salivary glands may swell, become sensitive, or become red as a result of sialadenitis. These include several tiny glands in the tongue, lips, cheeks, and palate in addition to the mouth's parotid, sublingual, and submaxillary glands, which are situated close to the ear. Any of these glands' secretions may be obstructed by salivary stones, or calculi.

Occasionally, the gland may get infected, resulting in fever and other problems. A characteristic shared by both the acute and chronic forms of sialadenitis is decreased salivary flow. During eating, the pain is more noticeable, and over 75% of patients report having dry mouth (xerostomia). Additional medical conditions include sarcoidosis, dehydration, malnutrition, radiation treatment for cancer, herpes, HIV, influenza A and type II, parainfluenza types I and II, salivary stones, mucus-blocking salivary ducts, tumors, Sjogren's syndrome, sarcoidosis, and inadequate oral hygiene, which can reduce salivary production and cause sialadenitis.

Growth Drivers for the Salivary Gland Infection Market

Rising infection rates

The need for treatment alternatives for salivary gland infections is mostly driven by the rising prevalence of infections, especially bacterial, fungal, and viral infections. The prevalence of illnesses such fungal infections, bacterial sialadenitis, and the mumps is rising, frequently as a result of poor dental hygiene, changing lifestyles, and the emergence of germs resistant to antibiotics. The increase in instances emphasizes the necessity of efficient therapeutic and diagnostic approaches.

Healthcare professionals are becoming more alert in identifying and treating these infections as knowledge of the significance of salivary gland health develops. Patients are encouraged to seek medical attention earlier as a result of this increased focus, which increases demand for cutting-edge treatment choices. Furthermore, the market's development potential is reinforced by the increased research activities and advancements in therapeutic technologies aimed at improving patient outcomes.

Improvements in lifestyle

Changes in lifestyle, such as nutrition and stress levels, have a big effect on dental health and raise the risk of salivary gland infections. Poor dental hygiene can result from diets heavy in sugar and processed foods, which in turn encourages bacterial development and raises the risk of illnesses. Furthermore, problems with the salivary glands can be made worse by dehydration and decreased salivation-both of which are prevalent in people who lead unhealthy lives.

Moreover, it is well recognized that high stress levels impair immune function, leaving people more vulnerable to illnesses. Prolonged stress can cause bad habits like teeth grinding, which can harm salivary gland function. The demand for efficient treatment choices is rising in tandem with the growing knowledge of these lifestyle-related dangers, underscoring the necessity of novel therapeutics to address these health issues.

Salivary Gland Infection Market Overview by Regions

With different development drivers and obstacles, the worldwide market for salivary gland infections is generally rising across all geographies. The industry is expected to develop as long as treatment choices become more widely known and accessible. An overview of the market by region is given below:

North America Salivary Gland Infection Market

United States

The increasing prevalence of illnesses like bacterial sialadenitis and viral infections like mumps has led to a thriving market for salivary gland infections in the US. The availability of efficient diagnostic tools and treatment choices is improved by an advanced healthcare infrastructure and a strong focus on research and innovation. The management of chronic diseases and improved oral health are two areas where early detection and action are aided. Furthermore, an elderly population is more prone to illnesses, which increases demand in the market. Overall, the market for salivary gland infections is expected to rise in the United States due to continual improvements in healthcare.

Europe Salivary Gland Infection Market

Germany

Germany's market for salivary gland infections is steadily expanding due to an older population and rising oral health awareness. There is an increasing need for efficient diagnosis and treatment alternatives due to the rising occurrence of diseases like mumps and sialadenitis. Market expansion is further supported by a concentration on research and development and an advanced healthcare infrastructure. Oral hygiene-related public health efforts improve patient outcomes by facilitating early diagnosis and intervention. Germany is positioned to be a major participant in the European salivary gland infection market as healthcare costs rise.

Asia Pacific Salivary Gland Infection Market

China

China's market for salivary gland infections is expanding significantly due to factors such changing eating patterns, growing urbanization, and growing awareness of oral health. Changes in lifestyle and environmental factors are contributing to an increase in the occurrence of illnesses like sialadenitis. Early infection diagnosis and management are being made easier by advancements in healthcare infrastructure and access to cutting-edge diagnostic and treatment alternatives. Market expansion is further supported by government measures focused at improving public health education. China is emerging as a major participant in the worldwide market for salivary gland infections as the healthcare industry continues to change.

Middle East & Africa Salivary Gland Infection Market

Saudi Arabia

Saudi Arabia's market for salivary gland infections is expanding as a result of improving oral health awareness and the prevalence of illnesses like sialadenitis. Dietary modifications and lifestyle choices are among the factors that increase the likelihood of developing these illnesses. The government's emphasis on enhancing access to specialized services and the infrastructure supporting healthcare improves diagnosis and treatment options. Furthermore, oral hygiene education programs run by public health organizations are essential for early detection and prevention. Saudi Arabia is establishing itself as an emerging market in the field of salivary gland infections as medical technology advances.

Salivary Gland Infection Company Analysis

The major participants in the Salivary Gland Infection market includes AbbVie Inc., Allergan plc., AstraZeneca, FUJIFILM Holdings Corporation, General Electric Company, GlaxoSmithKline plc., Merck & Co, Pfizer Inc., Siemens Healthcare GmbH.

Salivary Gland Infection Company News

In August 2022, t One of the world's first DNA screening programs for cancer and heart disease risk was introduced in Australia with free salivary DNA tests. The initiative is a national collaboration headed by Monash University in Australia.

In June 2022, Goodbody Health Inc. has introduced four new tests that use genetic analysis to estimate an individual's 10-year risk of developing heart disease or cancer. It is anticipated that these launches would accelerate this segment's future growth.

Types- Industry is divided into 2 viewpoints:

1. Diagnosis

2. Treatment

Application- Industry is divided into 4 viewpoints:

1. Hospital

2. Clinic

3. Household

4. Other

Countries- Industry is divided into 25 viewpoints:

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

1. Overviews

2. Key Person

3. Recent Developments & Strategies

4. Product Portfolio & Product Launch in Last 1 Year

5. Revenue

Company Analysis

1. AbbVie Inc.

2. Allergan plc.

3. AstraZeneca

4. FUJIFILM Holdings Corporation

5. General Electric Company

6. GlaxoSmithKline plc.

7. Merck & Co

8. Pfizer Inc.

9. Siemens Healthcare GmbH

Key Questions Answered in Report:

1. How big is the Salivary Gland Infection industry?

2. What is the Salivary Gland Infection growth rate?

3. Who are the key players in Salivary Gland Infection industry?

4. What are the factors driving the Salivary Gland Infection industry?

5. Which Region held the largest market share in the Salivary Gland Infection industry?

6. What segments are covered in the Salivary Gland Infection Market report?

Table of Contents

1. Introductions

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Driver
• 4.2 Challenges

5. Global Salivary Gland Infection Market

6. Global Salivary Gland Infection Market Share Analysis

• 6.1 By Types
• 6.2 By Application
• 6.3 By Country

7. Types - Global Salivary Gland Infection Market

• 7.1 Diagnosis
• 7.2 Treatment

8. Application - Global Salivary Gland Infection Market

• 8.1 Hospital
• 8.2 Clinic
• 8.3 Household
• 8.4 Other

9. Country - Global Industrial Hemp Market

• 9.1 North America
  • 9.1.1 United States
  • 9.1.2 Canada
• 9.2 Europe
  • 9.2.1 France
  • 9.2.2 Germany
  • 9.2.3 Italy
  • 9.2.4 Spain
  • 9.2.5 United Kingdom
  • 9.2.6 Belgium
  • 9.2.7 Netherlands
  • 9.2.8 Turkey
• 9.3 Asia Pacific
  • 9.3.1 China
  • 9.3.2 Japan
  • 9.3.3 India
  • 9.3.4 Australia
  • 9.3.5 South Korea
  • 9.3.6 Thailand
  • 9.3.7 Malaysia
  • 9.3.8 Indonesia
  • 9.3.9 New Zealand
• 9.4 Latin America
  • 9.4.1 Brazil
  • 9.4.2 Mexico
  • 9.4.3 Argentina
• 9.5 Middle East & Africa
  • 9.5.1 South Africa
  • 9.5.2 Saudi Arabia
  • 9.5.3 United Arab Emirates

10. Porter's Five Forces

• 10.1 Bargaining Power of Buyers
• 10.2 Bargaining Power of Suppliers
• 10.3 Degree of Rivalry
• 10.4 Threat of New Entrants
• 10.5 Threat of Substitutes

11. SWOT Analysis

• 11.1 Strength
• 11.2 Weakness
• 11.3 Opportunity
• 11.4 Threat

12. Key Players Analysis

• 12.1 AbbVie Inc.
  • 12.1.1 Overviews
  • 12.1.2 Key Person
  • 12.1.3 Recent Developments & Strategies
  • 12.1.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.1.5 Revenue
• 12.2 Allergan plc.
  • 12.2.1 Overviews
  • 12.2.2 Key Person
  • 12.2.3 Recent Developments & Strategies
  • 12.2.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.2.5 Revenue
• 12.3 AstraZeneca
  • 12.3.1 Overviews
  • 12.3.2 Key Person
  • 12.3.3 Recent Developments & Strategies
  • 12.3.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.3.5 Revenue
• 12.4 FUJIFILM Holdings Corporation
  • 12.4.1 Overviews
  • 12.4.2 Key Person
  • 12.4.3 Recent Developments & Strategies
  • 12.4.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.4.5 Revenue
• 12.5 General Electric Company
  • 12.5.1 Overviews
  • 12.5.2 Key Person
  • 12.5.3 Recent Developments & Strategies
  • 12.5.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.5.5 Revenue
• 12.6 GlaxoSmithKline plc.
  • 12.6.1 Overviews
  • 12.6.2 Key Person
  • 12.6.3 Recent Developments & Strategies
  • 12.6.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.6.5 Revenue
• 12.7 Merck & Co
  • 12.7.1 Overviews
  • 12.7.2 Key Person
  • 12.7.3 Recent Developments & Strategies
  • 12.7.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.7.5 Revenue
• 12.8 Pfizer Inc.
  • 12.8.1 Overviews
  • 12.8.2 Key Person
  • 12.8.3 Recent Developments & Strategies
  • 12.8.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.8.5 Revenue
• 12.9 Siemens Healthcare GmbH
  • 12.9.1 Overviews
  • 12.9.2 Key Person
  • 12.9.3 Recent Developments & Strategies
  • 12.9.4 Product Portfolio & Product Launch in Last 1 Year
  • 12.9.5 Revenue